Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014

Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014